NEW YORK (GenomeWeb) – A group of researchers led by Samuel Johnson of Kaiser Permanente Colorado is hoping to garner the attention of payors and health systems by showing how CYP2C19 genotyping can help them differentiate which acute coronary syndrome patients would fare best on low-cost generic clopidogrel, and which would be better off on higher priced branded agents, Daiichi Sankyo/Eli Lilly's Effient (prasugrel) and AstraZeneca's Brilinta (ticagrelor).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.